Modelling and simulation in the development and use of anti-cancer agents: an underused tool?

J Pharmacokinet Pharmacodyn. 2004 Dec;31(6):419-40. doi: 10.1007/s10928-005-5910-2.

Abstract

To help identify the role of modelling and simulation in the development of anti-cancer agents, their main advantages and the obstacles to their rational use, an expert meeting was organized by COST B15. This manuscript presents a synthesis of views expressed at that meeting and indicates future directions. The manuscript also shows some examples where modelling and simulation have proven to be of relevant value in the drug development process for anti-cancer agents.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Capecitabine
  • Clinical Trials as Topic
  • Computer Simulation*
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • Docetaxel
  • Drug Administration Schedule
  • Drug Design*
  • Fluorouracil / analogs & derivatives
  • Humans
  • Models, Biological*
  • Product Surveillance, Postmarketing
  • Quality of Life
  • Taxoids / therapeutic use
  • Vinblastine / analogs & derivatives
  • Vinblastine / therapeutic use

Substances

  • Antineoplastic Agents
  • Taxoids
  • Deoxycytidine
  • Docetaxel
  • vinflunine
  • Vinblastine
  • Capecitabine
  • Fluorouracil